Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
cmFOLFOXIRI + PD-1 Inhibitor vs mFOLFOX6 as Neoadjuvant Therapy for Locally Advanced Colon Cancer
NCT06890624Phase 2Not yet recruiting
- Sponsor
- Sun Yat-sen University
- Start
- Oct 2026
- Primary completion
- Oct 2029
01
Overview
Phase 2, randomised, open-label trial in colon cancer (2 arms), sponsored by Sun Yat-sen University. Primary endpoint: Pathologic Complete Response Rate at 1 year. Planned start Oct 2026; status: not yet recruiting.
02
Conditions
colon cancer
Beyond the preview
Go deeper on NCT06890624.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06890624.